Recombinant Rat Neuropilin-1 Fc Chimera (NS0-expressed), CF
Recombinant Rat Neuropilin-1 Fc Chimera (NS0-expressed), CF Summary
Product Specifications
Rat Neuropilin-1 (Phe22 - Ala810) Accession # Q9QWJ9 |
R | Rat Neuropilin-1 (Ser829 - Asp854) Accession # Q9QWJ9 |
IEGRDMD | Human IgG1 (Pro100 - Lys330) |
6-His tag |
N-terminus | C-terminus | ||||
R&D Systems rat Npn-1 may represent a previously unreported splice isoform of rat Npn-1.
Analysis
Product Datasheets
Carrier Free
CF stands for Carrier Free (CF). We typically add Bovine Serum Albumin (BSA) as a carrier protein to our recombinant proteins. Adding a carrier protein enhances protein stability, increases shelf-life, and allows the recombinant protein to be stored at a more dilute concentration. The carrier free version does not contain BSA.
In general, we advise purchasing the recombinant protein with BSA for use in cell or tissue culture, or as an ELISA standard. In contrast, the carrier free protein is recommended for applications, in which the presence of BSA could interfere.
566-NNS
Formulation | Lyophilized from a 0.2 μm filtered solution in Citrate Phosphate and NaCl. |
Reconstitution | Reconstitute at 100 μg/mL in sterile PBS. |
Shipping | The product is shipped at ambient temperature. Upon receipt, store it immediately at the temperature recommended below. |
Stability & Storage: | Use a manual defrost freezer and avoid repeated freeze-thaw cycles.
|
Reconstitution Calculator
Background: Neuropilin-1
Neuropilin-1 (Npn-1, previously neuropilin; also named CD304) is a 130 - 140 kDa type I transmembrane (TM) glycoprotein that regulates axon guidance and angiogenesis (1 - 4). The full-length 922 amino acid (aa) rat Npn-1 contains a 623 aa extracellular domain (ECD) that shares 98% aa identity with mouse and 93% aa identity with human, equine, bovine and canine Npn-1 (3, 4). The ECD contains two N-terminal CUB domains (termed a1a2), two domains with homology to coagulation factors V and VIII (b1b2) and a MAM (meprin) domain (c). In mouse and human, splice variants that lack the TM domain have been described and are either proven or presumed to be soluble antagonists (1, 5 - 7). The sema domains of Class III secreted semaphorins such as Sema3A bind Npn-1 a1a2 (8). Heparin, the heparin-binding forms of VEGF (VEGF165, VEGF-B and VEGF-E), PlGF (PlGF2), and the C-terminus of Sema3 bind the b1b2 region (8, 9). Npn-1 and Npn-2 share 48% aa identity within the ECD and can form homo- and hetero-oligomers via interaction of their MAM domains (1). Neuropilins show partially overlapping expression in neuronal and endothelial cells during development (1, 2). Both neuropilins act asco-receptors with plexins, mainly plexin A3 and A4, to bind class III semaphorins that mediate axon repulsion (10). However, only Npn-1 binds Sema3A, and only Npn-2 binds Sema3F (1). Both areco-receptors with VEGF R2 (also called KDR or Flk-1) for VEGF165 binding (1). Sema3A signaling can be blocked by VEGF165, which has higher affinity for Npn-1 (11). Npn-1 is preferentially expressed in developing or remodeling arteries (1, 2). Npn-1 is also expressed on dendritic cells and mediates DC-induced T cell proliferation (12).
- Bielenberg, D.R. et al. (2006) Exp. Cell Res. 312:584.
- Gu, C. et al. (2003) Dev. Cell 5:45.
- He, Z. and M. Tessier-Lavigne (1997) Cell 90:739.
- Soker, S. et al. (1998) Cell 92:735.
- Gagnon, M.L. et al. (2000) Proc. Natl. Acad. Sci. USA 97:2573.
- Cackowski, F.C. et al. (2004) Genomics 84:82.
- Rossignol, M. et al. (2000) Genomics 70:211.
- Gu, C. et al. (2002) J. Biol. Chem. 277:18069.
- Mamluk, R. et al. (2002) J. Biol. Chem. 277:24818.
- Yaron, A. et al. (2005) Neuron 45:513.
- Narazaki, M. and G. Tosato (2006) Blood 107:3892.
- Tordjman, R. et al. (2002) Nat. Immunol. 3477.
Product Specific Notices
This product or the use of this product is covered by U.S. Patents owned by The Regents of the University of California. This product is for research use only and is not to be used for commercial purposes. Use of this product to produce products for sale or for diagnostic, therapeutic or drug discovery purposes is prohibited. In order to obtain a license to use this product for such purposes, contact The Regents of the University of California.U.S. Patent # 6,054,293, 6,623,738, and other
Citations for Recombinant Rat Neuropilin-1 Fc Chimera (NS0-expressed), CF
R&D Systems personnel manually curate a database that contains references using R&D Systems products. The data collected includes not only links to publications in PubMed, but also provides information about sample types, species, and experimental conditions.
3
Citations: Showing 1 - 3
Filter your results:
Filter by:
-
Exogenous recombinant dimeric neuropilin-1 is sufficient to drive angiogenesis.
Authors: Uniewicz KA, Cross MJ, Fernig DG
J. Biol. Chem., 2010-10-18;286(1):12-23.
Species: Human
Sample Types: Whole Cells
Applications: Bioassay -
Sulfated polysaccharides identified as inducers of neuropilin-1 internalization and functional inhibition of VEGF165 and semaphorin3A.
Authors: Narazaki M, Segarra M, Tosato G
Blood, 2008-02-13;111(8):4126-36.
Species: Human
Sample Types: Recombinant Protein
Applications: Binding Assay -
In vivo analysis reveals a critical role for neuropilin-1 in cranial neural crest cell migration in chick.
Authors: McLennan R, Kulesa PM
Dev. Biol., 2006-08-10;301(1):227-39.
Species: Chicken
Sample Types: In Vivo
Applications: In Vivo
FAQs
No product specific FAQs exist for this product, however you may
View all Proteins and Enzyme FAQsReviews for Recombinant Rat Neuropilin-1 Fc Chimera (NS0-expressed), CF
There are currently no reviews for this product. Be the first to review Recombinant Rat Neuropilin-1 Fc Chimera (NS0-expressed), CF and earn rewards!
Have you used Recombinant Rat Neuropilin-1 Fc Chimera (NS0-expressed), CF?
Submit a review and receive an Amazon gift card.
$25/€18/£15/$25CAN/¥75 Yuan/¥2500 Yen for a review with an image
$10/€7/£6/$10 CAD/¥70 Yuan/¥1110 Yen for a review without an image